Effectiveness of methylphenidate and PUFA for the treatment of patients with ADHD: A double-blinded randomized clinical trial
Background: In some children with ADHD, sub-optimal levels of various nutrients including PUFA especially omega-3 has been observed, and contradictory reports exist on the results of studies conducted on the positive therapeutic effects of PUFA in patients with ADHD. Objective: The aim of this st...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Electronic Physician
2017-05-01
|
| Series: | Electronic Physician |
| Subjects: | |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5498708/ |
| Summary: | Background: In some children with ADHD, sub-optimal levels of various nutrients including PUFA especially
omega-3 has been observed, and contradictory reports exist on the results of studies conducted on the positive
therapeutic effects of PUFA in patients with ADHD.
Objective: The aim of this study was to investigate the effectiveness of methylphenidate and PUFA on treatment
of patients with ADHD in Zahedan, Iran.
Methods: In this clinical trial, 40 children between 6 and 12 years of age with ADHD were investigated in
Zahedan in 2014. Patients were randomly divided into two groups of methylphenidate plus PUFA and
methylphenidate plus placebo. ADHD rating scale was filled before and after the study for patients of both
groups. Finally, data were analyzed using SPSS18, paired-samples t-test and chi-square.
Results: Mean age of patients was 2.9±1.8 years. Thirty-three children (82.5%) were boys and seven children
(17.5%) were girls. Mean severity of signs in the group under methylphenidate plus PUFA treatment was
39.9±4.9 before treatment and 20.1±6.0 after 8 weeks of treatment (p<0.001). Mean severity of signs in the group
under methylphenidate plus placebo treatment was 41.2±2.7 before treatment and 26.1±9.0 after 8 weeks of
treatment (p<0.001). Mean reduction in the severity of symptoms in the group under methylphenidate therapy
was 19.7±5.9 and in PUFA and placebo group it was 15.1±9.3 (p<0.067). Response to treatment (a reduction of
at least 25% in the signs) in the group taking methylphenidate plus PUFA was 90% (18 patients) and in
methylphenidate plus placebo group, it was 60% (12 patients) (p=0.028).
Conclusion: This study shows that PUFA is an efficient nutrient to treat ADHD and it can be used to treat
patients. However, definitive conclusion requires repeating the study with a larger sample and longer study
period.
Trial registration: The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the
Irct ID: IRCT2015092724209N2.
Funding: The authors received no financial support for the research, authorship, and/or publication of this article |
|---|---|
| ISSN: | 2008-5842 2008-5842 |